Eriko Yamamoto

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav et al. · The Lancet Oncology · 2021 · 392 citations

Oncology, Gastrointestinal Oncology, Colorectal Cancer +5

Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate

Masao Tanihara, Yasuo Suzuki, Eriko Yamamoto et al. · Journal of Biomedical Materials Research · 2001 · 205 citations

Tissue Engineering, Engineering, Biomaterials Design +24

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Taroh Satoh, Kyung Hee Lee, Sun Young Rha et al. · Gastric Cancer · 2014 · 114 citations · Full text

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav et al. · Journal of Clinical Oncology · 2020 · 63 citations

Immunology, Immunoediting, Pathology +20

Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release

Naofumi Chinen, Masao Tanihara, Miyako Nakagawa et al. · Journal of Biomedical Materials Research Part A · 2003 · 57 citations